ico_admin

Phase Ia and Ib Double-Blind Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (ICo-019) in Healthy Human Subjects

ico_admin2021-02-21T21:39:10+00:00October 1st, 2020|2020, Presentations|

ico_admin2021-02-21T21:39:37+00:00October 1st, 2020|2020, Presentations|

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)

ico_admin2021-02-20T03:20:09+00:00August 31st, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-20T03:19:36+00:00July 30th, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)

ico_admin2021-02-20T03:19:02+00:00July 13th, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-20T03:18:27+00:00June 22nd, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-20T03:17:48+00:00May 29th, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)

ico_admin2021-02-20T03:17:14+00:00May 19th, 2020|2020, Press Releases|

April 27, 2020, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2021-02-20T03:16:37+00:00April 27th, 2020|2020, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-20T03:15:51+00:00April 15th, 2020|2020, Press Releases|